Drugs / EXG34217
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04211714 | Apr 2021 → Oct 2026 expected | bone marrow failure syndrome, telomere syndrome | Elixirgen Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05868499 Background | Jan 2024 → Jan 2027 expected | pulmonary fibrosis and/or bone marrow failure, telomere-related | Elixirgen Therapeutics, Inc. | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXG34217 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05868499 ↗ |
| Modality | Cell therapy | “EXG34217, the term given for autologous CD34+ hematopoietic stem cells from patients with TBD exposed to a temperature-sensitive Sendai virus vector encoding human ZSCAN4 at...” PMID 39998303 ↗ Feb 2025 |